The global Epilepsy Therapeutics market was worth around USD 10.10 billion in 2021 and is estimated to grow to about USD 12.13 billion by 2028, with a compound annual growth rate (CAGR) of approximately 3.10 percent over the forecast period
The global Epilepsy Therapeutics market was worth around USD 10.10 billion in 2021 and is estimated to grow to about USD 12.13 billion by 2028, with a compound annual growth rate (CAGR) of approximately 3.10 percent over the forecast period The report analyzes the Epilepsy Therapeutics market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Epilepsy Therapeutics market.
Epilepsy Therapeutics Market: Overview
Epilepsy Therapeutics refers to chronic neurological disorder which causes constant and unfounded seizures. An individual suffering from Epilepsy Therapeutics tends to have seizures with no explanation. In Epilepsy Therapeutics, the brain activity becomes abnormal, resulting in recurrent seizures that are short episodes of involuntary movement, which may involve a part of the body or the entire body. The increase in the number of accidents and brain injuries and the high rate of post-traumatic Epilepsy Therapeutics (PTE) and post-traumatic seizure (PTS) occurrence in patients with brain injuries are the major factors driving the Epilepsy Therapeutics treatment market.
Furthermore, innovation of new treatment products with better efficiency is expected to further drive this market. Rising number of mergers and acquisitions, new product launches, and increasing number of collaborations and partnerships are some of the latest trends that have been observed in the global Epilepsy Therapeutics market. Besides development of new drugs and treatment options, approval and launch of new products extend profitable opportunities to the Epilepsy Therapeutics treatment market players in the forecast period.
In Addition, development of highly efficacious products, having less side-effects, and better outcomes are likely to propel the Epilepsy Therapeutics market Neurological disorders have become a matter of concern for medical researchers who are looking at optimizing medical treatments. Furthermore, the adoption of anti-epileptics due to increasing seizures and Epilepsy Therapeutics cases, and a rise in research and development is driving the growth of Epilepsy Therapeutics market. .However, factors such as lack of awareness about the condition some developing regions and reluctance to adopt Epilepsy Therapeutics medications in some regions are restraining the growth of the Epilepsy Therapeutics market over the upcoming years.
The new coronavirus has spread worldwide in a relatively short period and has become a pandemic. Many affected patients have symptoms such as dry cough, tiredness, dyspnea, and fever. However, the infection with Covid-19 disrupts multiple tissues, including the kidney, liver, and nervous system. Common neurological symptoms of Covid-19 infection include delirium, depression, fever, and loss of smell and taste. It can cause stroke and epilepsy in rare cases. Furthermore, due to concerns about patient-to-patient transmission, standby admissions in hospitals with COVID-19 inpatients or in areas with widespread COVID-19 infection have been severely limited.
According to an article published in March 2020 titled "Epilepsy and COVID-19: Updated Evidence and Narrative Review," a survey of 212 pediatric neurologists from 49 countries found that in-person outpatient visits have decreased, and telemedicine use has increased during the pandemic. This has risen the demand for efficient epilepsy cures and medications.
Moreover, the growing R&D investments towards COVID 19 treatments may also contribute towards the epilepsy market growth.
Epilepsy Therapeutics Market: Growth Drivers
Active Government Support and Investments to Expedite Market Growth
Governmental initiatives to improve the healthcare sectors and higher investments in R&D is anticipated to expand at a notable growth of Epilepsy Therapeutics market during the forecast period. Rise in the number of approvals by government bodies is providing beneficial for the patients in controlling the seizures. This is projected to fuel the adoption of anticonvulsant and boost the market growth over the upcoming years.
Epilepsy Therapeutics Market: Restraints
Epilepsy Medicine shortage to hamper the market growth
One of the major factors restraining the growth of Epilepsy Therapeutics market during the forecast period is steep rise in medicine shortage. Patients are stockpiling these medicines as there is a shortage of drugs in pharmacies which has raised an alarm in investigating the medicine supply chain globally. This is ultimately affecting the global Epilepsy Therapeutics market as the market becomes less desirable for Epilepsy Therapeutics medications.
Global Epilepsy Therapeutics Market: Segmentation
The global Epilepsy Therapeutics market is segregated based on Product, distribution channel, end-user, and region.
Based on distributional channel, the global Epilepsy Therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is projected to dominate the global market. growing number of hospitals, along with adequate reimbursement policies provided by these settings, are some of the major factors responsible for higher growth of hospital pharmacy over the upcoming years. This is eventually responsible for the adoption of antiepileptic drugs by the hospital pharmacies globally.
Based on product market has been classified into first generation Epilepsy Therapeutic second-generation Epilepsy Therapeutics and third generation Epilepsy Therapeutics. The second-generation epilepsy therapeutics segment is expected to hold a significant share of the global epilepsy therapeutics. This is due to increased penetration in the market and better effectiveness as compared to first generation Epilepsy Therapeutics
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
North America dominates the global market for Epilepsy Therapeutics during the forecast period. This is majorly due to higher investments in R&D, increasing awareness and availability of advanced Epilepsy Therapeutics drugs in this region. Moreover, improved healthcare facilities are driving the market for Epilepsy Therapeutics in North America during the forecast period.
Asia Pacific is witnessing a significant growth in the global Epilepsy Therapeutics market over the upcoming years. Due government initiatives in the field, Increased awareness and technological advancement in field is fueling the growth of global Epilepsy Therapeutics market.
Some of the main competitors dominating key players functioning in the global Epilepsy Therapeutics market include. BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA and Zogenix Inc.
Global Epilepsy Therapeutics market is segmented as follows:
By Types Covered
By End Users Covered:
By Products Covered:
By Distribution Channels Covered:
Epilepsy is a severe neurological disorder with unpredictable seizures. Epilepsy affects millions of people all over the world and it is the one of the most common neurological disorder. Seizures may be classified as generalized seizures, focal seizures, and other seizures. Among these, focal seizures are the most common type of seizures. Generalized seizures comprise tonic seizures, myoclonic seizures, absences, clonic seizures, and atonic seizures. Focal seizures involve complex partial seizures and secondary generalized clonic/tonic seizures (sGCTS). When a group of nerve cells or neurons in the brain send wrong or multiple signals to the body, at that time seizures occur. The growing prevalence of neurological disorders globally is expected to propel the growth of the global market over the coming years. Moreover, increasing awareness about treatment and diagnostics of neurological disorders and easy availability of drugs in the developed market is expected to propel the growth of the market in the near future.
The global epilepsy therapeutics market is segmented as product type, distribution channel, and by geography. Based on product type, the epilepsy therapeutics market is segmented into first-generation epilepsy therapeutics, second-generation epilepsy therapeutics, and third-generation epilepsy therapeutics. On the basis of the distribution channel, the epilepsy therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
North America accounted for the dominant share in the global market for epilepsy therapeutics in 2017 and is anticipated to continue with its regional supremacy over the forthcoming years as well. For epilepsy drugs, North America is the most mature market and hence is expected to grow slowly over the forecast period. The high government support, strong research and development platform, and strong pipeline for epilepsy drugs for the development of next-generation anti-epileptic drugs are the key factors contributing for the high share of North America epilepsy therapeutics market.
Asia Pacific is expected to register the highest CAGR in the global epilepsy therapeutics market in the coming years. The growing awareness about advanced anti-epileptic drug treatment in emerging economies is expected to boost the growth of Asia Pacific epilepsy therapeutics market over the forecast period.
Some of the key players in the epilepsy therapeutics market are Eisai Co., Ltd., GlaxoSmithKline, Pfizer Inc., UCB S.A., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceutical, Abbott, Novartis AG, and Shire. The growing prevalence of epilepsy and increasing competition among the key players in the market for the development of advanced drugs is expected to propel the growth of the market over the coming years.